US › Healthcare

Edesa Biotech Inc (EDSA)

US · Healthcare · Biotechnology

$4.14+6.98%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.4M

EPS

$-0.60

EPS estimate

$-0.44

EPS came in at -0.60 against a street estimate of -0.44 — a miss of 36.4%.

Key statistics

Market cap

$40.8M

Forward P/E

0.2

P/B

102.70

Book value

$0.04

EPS (TTM)

$-1.72

52-week high

$20.32

52-week low

$0.72

50-day MA

$5.52

200-day MA

$5.34

Beta

1.06

Analyst view

Analysts rate Edesa Biotech Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $16.33.

Shareholding

Insiders

13.50%

Institutions

37.44%

Largest institutional holders

Fund	Stake
Velan Capital Investment Management LP	8.58%
Rubric Capital Management LP	7.13%
Perceptive Advisors LLC	5.84%
Millennium Management LLC	5.83%
Jane Street Group LLC	1.20%
Vanguard Capital Management, LLC	0.89%
Geode Capital Management, LLC	0.80%
Vanguard Fiduciary Trust Co	0.40%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Edesa Biotech Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.